About XIMINO

“controlled-dose capsular” technology

an innovative, polymer-based delivery system1

XIMINO | The innovative 'controlled-dose capsular' technology

The innovative “controlled-dose capsular” technology encloses a small, uniform amount of the active pharmaceutical ingredient in a patented polymer wrapper1

  • Provides a steady, controlled release of minocycline2,3
  • The polymer technology in XIMINO capsules is partially resistant to dissolution so the minocycline is released over time, in a controlled manner2,3
XIMINO | The proven power of minocycline (N=924)

The proven power of minocycline (N=924) now available in an ER capsule4

  • Patients with moderate to severe inflamed acne experienced significant improvement in lesion count4
XIMINO | The innovative 'controlled-dose capsular' technology
XIMINO | The innovative 'controlled-dose capsular' technology
XIMINO (1 mg/kg) Placebo

Compared to the placebo group, patients treated with ER minocycline monotherapy saw a significantly greater improvement in inflammatory lesions.4

The safety and efficacy of minocycline hydrochloride in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris was assessed in two 12-week, multi-center, randomized, double-blind, placebo-controlled trials in 924 subjects ≥ 12 years.

Patients also saw approximately twice the treatment success.*6

*Treatment success was defined as the proportion of subjects with a score of 0 (clear) or 1 (almost clear) on the Evaluator’s Global Severity Assessment.

The safety and efficacy of minocycline hydrochloride in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris was assessed in two 12-week, multi-center, randomized, double-blind, placebo-controlled trials in 924 subjects ≥ 12 years.

The proven efficacy of minocycline (N=924) in an ER capsule4

Patients with moderate to severe inflamed acne experienced significant improvement in lesion count.

XIMINO | Slower, steadier release with extended release
ER Mino (XIMINO) IR Mino (Brand) IR Mino (Generic)

Comparative drug-release data of minocycline formulation2

  • Slow, steady release of XIMINO capsule
    • <20% released at 15 minutes2
  • ER minocycline release is slow and steady2,3
  • Generic formulation exhibited a rapid release of minocycline, with 100% released in less than 15 minutes4

Clinical data of XIMINO was based on studies done with ER minocycline tablets.

Avoid a spike by using XIMINO ER capsules vs. IR minocycline.

*XIMINO is a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.1

XIMINO | ER minocylcine has a vestibular adverse event profile similar to placebo

Clinical data of XIMINO was based on studies done with ER minocycline tablets.

Together, Capsular Minotab Technology and weight-based dosing allow a side effect profile similar to placebo [N=1038]2,4

Occurrence of vestibular adverse events is similar between XIMINO and placebo. Slow, steady release and weight-based dosing are believed to be the reasons for the lower risk of AVAEs with XIMINO compared to IR minocycline.2,4

Help patients save on their XIMINO prescription

XIMINO | Rebate Card